The Biocis pharma oy pharmaceuticals company has entered into several healthcare deals and alliances. The company recently acquired Denali Therapeutics and is developing an experimental Parkinson’s disease therapy called DNL151. This therapy has recently completed a phase 1b trial. This deal has a potential value of over $8 billion. It is not yet clear what the next steps will be for the company.
This year has seen many deals involving some of the biggest names in biopharmaceutical companies.
One of the top three deals in April alone involved 256 different companies. GlobalData’s Financial Deals database tracks market activity, including debt offerings, equity offerings, asset sales, acquisitions, and venture financing. The company signed a licensing deal with Daiichi Sankyo, which will allow it to develop an antibody-drug conjugate therapy that will target a new type of cancer-causing virus.
The company’s CEO and president is Dr. Leino, who has over 20 years of experience in life science business. He founded BioCis Pharma Ltd. and previously served as the first CEO of Laurantis Pharma Ltd. He has also held numerous R&D management positions in the pharmaceutical industry. He holds a PhD in biochemistry and an Adjunct Professor in immunology at the University of Turku.
While oncology and rare disease are the most common areas of focus for M&A, the other two sectors include immunology/inflammation and immunology/research. The latest large deal was Novo Nordisk’s $13.7 billion acquisition of RNA interference specialist Dicerna, tapped into the potential of switching off target proteins in the body. Sanofi recently acquired Translate Bio, which has a mRNA platform to express proteins. Those acquisitions were largely driven by the success of the COVID-19 vaccine.